Merck Net Worth
Merck Net Worth Breakdown | MRK |
Merck Net Worth Analysis
Merck's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Merck's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Merck's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Merck's net worth analysis. One common approach is to calculate Merck's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Merck's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Merck's net worth. This approach calculates the present value of Merck's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Merck's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Merck's net worth. This involves comparing Merck's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Merck's net worth relative to its peers.
Enterprise Value |
|
To determine if Merck is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Merck's net worth research are outlined below:
| Merck Company generated a negative expected return over the last 90 days | |
| Over 80.0% of the company shares are owned by institutional investors | |
| On 8th of January 2025 Merck paid $ 0.81 per share dividend to its current shareholders | |
| Latest headline from prnewswire.com: MRK INVESTOR ALERT Bronstein, Gewirtz Grossman LLC Announces that Merck Co., Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit |
Merck Quarterly Good Will |
|
Merck uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Merck Company. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Merck's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 25th of April 2024 Upcoming Quarterly Report | View | |
| 6th of August 2024 Next Financial Report | View | |
| 31st of March 2024 Next Fiscal Quarter End | View | |
| 6th of February 2025 Next Fiscal Year End | View | |
| 31st of December 2023 Last Quarter Report | View | |
| 31st of December 2023 Last Financial Announcement | View |
Know Merck's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Merck is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Merck Company backward and forwards among themselves. Merck's institutional investor refers to the entity that pools money to purchase Merck's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Bank Of New York Mellon Corp | 2024-12-31 | 24.2 M | Ubs Asset Mgmt Americas Inc | 2024-12-31 | 21.5 M | Charles Schwab Investment Management Inc | 2024-12-31 | 20.1 M | Franklin Resources Inc | 2024-12-31 | 19.9 M | Legal & General Group Plc | 2024-12-31 | 19.5 M | Deutsche Bank Ag | 2024-12-31 | 19.2 M | Royal Bank Of Canada | 2024-12-31 | 18.4 M | Ubs Group Ag | 2024-12-31 | 17.3 M | Goldman Sachs Group Inc | 2024-12-31 | 17.1 M | Vanguard Group Inc | 2024-12-31 | 251.1 M | Blackrock Inc | 2024-12-31 | 222.1 M |
Follow Merck's market capitalization trends
The company currently falls under 'Mega-Cap' category with a total capitalization of 231.28 B.Market Cap |
|
Project Merck's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.01 | 0.01 | |
| Return On Capital Employed | 0.04 | 0.04 | |
| Return On Equity | 0.38 | 0.32 |
When accessing Merck's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Merck's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Merck's profitability and make more informed investment decisions.
Evaluate Merck's management efficiency
Merck Company has Return on Asset of 0.1053 % which means that on every $100 spent on assets, it made $0.1053 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.4169 %, implying that it generated $0.4169 on every 100 dollars invested. Merck's management efficiency ratios could be used to measure how well Merck manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to 0.01. The value of Return On Capital Employed is expected to slide to 0.04. At this time, Merck's Total Current Liabilities is quite stable compared to the past year. Liabilities And Stockholders Equity is expected to rise to about 128.8 B this year, although the value of Non Current Liabilities Total is projected to rise to (42.3 B).| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 17.54 | 18.41 | |
| Tangible Book Value Per Share | 17.54 | 18.41 | |
| Enterprise Value Over EBITDA | 9.38 | 11.09 | |
| Price Book Value Ratio | 5.67 | 6.90 | |
| Enterprise Value Multiple | 9.38 | 11.09 | |
| Price Fair Value | 5.67 | 6.90 | |
| Enterprise Value | 252.8 B | 265.4 B |
The strategic initiatives led by Merck's management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Enterprise Value Revenue 3.9649 | Revenue | Quarterly Revenue Growth 0.068 | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Merck insiders, such as employees or executives, is commonly permitted as long as it does not rely on Merck's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Merck insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Chirfi Guindo over three weeks ago Acquisition by Chirfi Guindo of 28158 shares of Merck at 97.94 subject to Rule 16b-3 | ||
Smart Dalton over six months ago Disposition of 612 shares by Smart Dalton of Merck subject to Rule 16b-3 | ||
Smart Dalton over six months ago Disposition of 381 shares by Smart Dalton of Merck subject to Rule 16b-3 | ||
Smart Dalton over six months ago Disposition of 6224 shares by Smart Dalton of Merck at 117.89 subject to Rule 16b-3 | ||
Smart Dalton over six months ago Disposition of 6224 shares by Smart Dalton of Merck at 117.89 subject to Rule 16b-3 | ||
Peter Wendell over a year ago Merck exotic insider transaction detected | ||
Peter Wendell over a year ago Acquisition by Peter Wendell of 270 shares of Merck subject to Rule 16b-3 |
Merck Corporate Filings
10K | 25th of February 2025 Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance | ViewVerify |
F4 | 20th of February 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 14th of February 2025 Other Reports | ViewVerify | |
8K | 4th of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
Merck Earnings per Share Projection vs Actual
Merck Corporate Directors
| Thomas Glocer | Lead Independent Director | Profile | |
| Christine Seidman | Independent Director | Profile | |
| Kathy Warden | Independent Director | Profile | |
| Paul Rothman | Independent Director | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Merck Company. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Merck. If investors know Merck will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Merck listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.33) | Dividend Share 3.08 | Earnings Share 6.74 | Revenue Per Share | Quarterly Revenue Growth 0.068 |
The market value of Merck Company is measured differently than its book value, which is the value of Merck that is recorded on the company's balance sheet. Investors also form their own opinion of Merck's value that differs from its market value or its book value, called intrinsic value, which is Merck's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Merck's market value can be influenced by many factors that don't directly affect Merck's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Merck's value and its price as these two are different measures arrived at by different means. Investors typically determine if Merck is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Merck's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.